KR101266148B1 - A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical - Google Patents
A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical Download PDFInfo
- Publication number
- KR101266148B1 KR101266148B1 KR1020110027290A KR20110027290A KR101266148B1 KR 101266148 B1 KR101266148 B1 KR 101266148B1 KR 1020110027290 A KR1020110027290 A KR 1020110027290A KR 20110027290 A KR20110027290 A KR 20110027290A KR 101266148 B1 KR101266148 B1 KR 101266148B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- oligosaccharides
- acid bacteria
- red ginseng
- weight
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 50
- 241000894006 Bacteria Species 0.000 title claims abstract description 39
- 239000004310 lactic acid Substances 0.000 title claims abstract description 39
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 39
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 28
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 26
- 240000004371 Panax ginseng Species 0.000 title claims abstract description 10
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 10
- 235000013305 food Nutrition 0.000 title claims description 11
- 239000000843 powder Substances 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 241000186660 Lactobacillus Species 0.000 claims abstract description 12
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 12
- 239000006041 probiotic Substances 0.000 claims abstract description 11
- 235000018291 probiotics Nutrition 0.000 claims abstract description 11
- 230000000529 probiotic effect Effects 0.000 claims abstract description 10
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims description 17
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 229930182494 ginsenoside Natural products 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 239000004267 EU approved acidity regulator Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000003765 sweetening agent Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 4
- 244000005709 gut microbiome Species 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims 2
- 235000013361 beverage Nutrition 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 244000005706 microflora Species 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000037406 food intake Effects 0.000 description 4
- -1 fructose oligosaccharide Chemical class 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical class OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 2
- 229940107187 fructooligosaccharide Drugs 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 2
- 229960000511 lactulose Drugs 0.000 description 2
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011265 semifinished product Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 홍삼(紅蔘, Panax ginseng C.A. Meyer), 혼합 유산균 및 올리고당류를 모두 분말로 형성하여 함유하는 조성물에 관한 것이다.
본 발명에 사용되는 혼합 유산균은 락토바실러스(Lactobacillus) 및 비피도박테리움 (Bifidobacterium) 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하는 것을 특징으로 하고 있다.The present invention relates to a composition comprising red ginseng (紅 蔘, Panax ginseng CA Meyer), mixed lactic acid bacteria and oligosaccharides in powder form.
The mixed lactic acid bacteria used in the present invention are characterized by including two or more types of probiotic lactic acid bacteria contained in Lactobacillus and Bifidobacterium strains.
Description
본 발명은 홍삼(紅蔘, Panax ginseng C.A. Meyer), 혼합 유산균 및 올리고당류를 모두 분말로 형성하여 함유하는 조성물에 관한 것이다.The present invention relates to a composition comprising red ginseng (紅 蔘, Panax ginseng CA Meyer), mixed lactic acid bacteria and oligosaccharides in powder form.
본 발명에 사용되는 혼합 유산균은 락토바실러스(Lactobacillus) 및 비피도박테리움 (Bifidobacterium) 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하는 것을 특징으로 하고 있다.The mixed lactic acid bacteria used in the present invention are characterized by including two or more types of probiotic lactic acid bacteria contained in Lactobacillus and Bifidobacterium strains.
홍삼(紅蔘, Panax ginseng C.A. Meyer)은 오갈피나무과에 속하는 다년생 풀인 4~6년 근 수삼(水蔘)을 선별하여 껍질을 벗기지 않은 상태로 증기에 쪄서 말린 것이다.Red ginseng ( Panax ginseng CA Meyer) is a perennial herb belonging to the Ogalpiaceae, selected for 4-6 years of fresh ginseng and dried in steam without peeling.
한의학적으로는, 성질은 약간 따듯하고 맛은 달고 약간 쓰며, 비, 폐, 심장으로 들어가 원기를 보충하고 진액을 만드는 등, 건강 증진과 질병 예방의 효과가 있는 대표적 한약재로 사용되어 왔다.In oriental medicine, it has been used as a representative herbal medicine with the effect of promoting health and preventing disease, such as being slightly warm, sweet and slightly bitter, entering the rain, lungs, and heart to replenish the energy and make a essence.
특히 홍삼에는 생리활성 유효 성분으로서 진세노사이드(ginsenoside)가 함유되어 있는데, 그 가운데에서 특히 진세노사이드(ginsenoside) Rb1, Rg1및Rc의 함유량이 비교적 높은 것으로 알려져 있다.
In particular, red ginseng contains ginsenosides as physiologically active ingredients, and among them, ginsenosides Rb 1 , Rg 1 and Rc are known to have a relatively high content.
그런데 진세노사이드(ginsenoside)는 분자량이 큰데도 불구하고 인체의 위산 및 소화효소가 이를 잘 분해하지 못하는 등의 원인으로 인체 내 소화 흡수율이 매우 낮은 것으로 연구되어 왔다.By the way, ginsenoside (ginsenoside) has been studied to have a very low digestive absorption rate in the human body due to the fact that the stomach acid and digestive enzymes of the human body does not break down even though the molecular weight is large.
여기에서, 분자량을 살펴보면, 진세노사이드 Rb1 은 1109.29, 진세노사이드Rg1은 801.01, 진세노사이드 Rc는11079.27에 이른다.
Here, looking at the molecular weight, ginsenoside Rb1 is 1109.29, ginsenoside Rg1 is 801.01, ginsenoside Rc is 11079.27.
논문 “Studies on absorption, distribution, and metabolism of ginseng in humans after oral administration”(Jayeul LEE 외 5인, Journal of Ethnopharmacology, Vol. 122, 143~148, 2009.02)에는, 한국인 98명을 조사한 결과 20% 가량은 장내 미생물이 진세노사이드(ginsenoside) Rb1을 컴파운드(compound) K로 전환시키지 못한다고 기재되어 있다.In the paper “Studies on absorption, distribution, and metabolism of ginseng in humans after oral administration” (Jayeul LEE et al. 5, Journal of Ethnopharmacology, Vol. 122, 143-148, 2009.02), about 20% of Koreans were surveyed. Has been described that intestinal microorganisms do not convert ginsenoside Rb1 to compound K.
즉 한국인의 20% 가량은 홍삼을 섭취하더라도 그 효과를 보기 어렵다고 추정될 수 있는데, 이는 신장기능이 좋은 반면에 장 기능이 좋지 못한 소음인 비율인 20~30% 에 해당되는 수치에 해당된다.
In other words, about 20% of Koreans may not be able to see the effect even if they consume red ginseng. This is equivalent to 20-30%, which is the ratio of noise that is not good in intestinal function while having good kidney function.
또한 논문 “인삼사포닌류의 체내동채와 효능에 관한 생화학적 연구현황”(주충노, 고려인삼학회지, Vol. 17, No.13, 250~286, 1993년)은, 실험동물에 인삼을 경구 투여한 후 진세노사이드의 흡수 결과를 논하고 있는데, 위장에서 부분적으로 분해가 되고 대부분이 배설되며, 흡수율이 매우 낮다는 것이 기재되어 있다.
In addition, the study "Biochemical Studies on the Body Composition and Efficacy of Ginseng Saponins" (Joo Choong-no, Journal of Korean Ginseng Society, Vol. 17, No. 13, 250-286, 1993), Later, the results of the absorption of ginsenosides are discussed, with partial degradation in the gastrointestinal tract, the majority being excreted, and the absorption being very low.
따라서 홍삼이 포함하는 유효성분으로서의 진세노사이드(ginsenoside)를 흡수하여 건강 증진 효과를 얻기 위해서는, 장 내 존재하는 미생물총을 활성화할 수 있는 물질과 더불어서 함께 섭취하는 것이 필요하다 하겠다.Therefore, in order to absorb the ginsenoside as an active ingredient included in red ginseng to obtain a health promoting effect, it is necessary to ingest together with a substance that can activate the microflora present in the intestine.
왜냐하면 홍삼을 경구 섭취할 경우, 소장에서 제대로 흡수가 되지 않고 대장에 도달한 후에야 미생물이 분비하는 효소에 의해 분해되어 흡수된다고 볼 수 있으며, 결국 장내에 존재하는 미생물총의 활성에 따라 홍삼의 효과가 좌우된다고 할 수 있기 때문이다.
Because red ginseng is taken orally, it is not absorbed properly in the small intestine, but can be decomposed and absorbed by enzymes secreted by the microorganisms after reaching the large intestine. It can be said that it depends.
한편 프로바이오틱(probiotics) 유산균을 기능성 식품에 사용하기 위하여 유산균의 잠재력에 대한 평가나 선발기준에 대한 연구가 광범위하게 진행되어 왔다.On the other hand, in order to use probiotics lactic acid bacteria in functional foods, researches on the evaluation or selection criteria of lactic acid bacteria potential have been extensively conducted.
여기에서, 프로바이오틱이란 숙주의 장내 미생물 균형을 향상시킴으로써 건강 증진 효과를 나타내는 활성 미생물 식이 보충제를 의미하여, 대표적인 프로바이오틱으로는 유산균을 들 수 있겠다.Here, probiotic means an active microbial dietary supplement that exhibits a health promoting effect by improving the intestinal microbial balance of the host, and a representative probiotic may include lactic acid bacteria.
일 예로, 논문 “과민성 대장 증후군 환자에서의 락토바실러스 애시도필러스(Lactobacillus acidophilus)-SDC 2012, 2013의 효과”(신동현 외 1인, 대한소화관운동학회지, Vol. 25, 90~91, 2009년)에는, 락토바실러스 애시도필러스가 과민성 대장 증후군 환자들에게서 증상 완화 효과가 있다는 것이 기재되어 있다.
For example, the article “Effects of Lactobacillus acidophilus- SDC 2012, 2013 in patients with irritable bowel syndrome” (Shin Dong-hyun and others, Journal of the Korean Gastrointestinal Kinesiology, Vol. 25, 90 ~ 91, 2009) ) Shows that Lactobacillus ashidophilus has a symptomatic effect in patients with irritable bowel syndrome.
따라서 홍삼을 경구 섭취할 경우, 장 내 존재하는 미생물총을 활성화할 수 있는 프로바이오틱 유산균과 더불어 섭취함으로써, 홍삼의 효과를 증진시킬 수 있는 기능성 조성물의 개발이 절실하다 하겠다.Therefore, oral ingestion of red ginseng, by ingesting with probiotic lactic acid bacteria that can activate the microflora present in the intestine, the development of a functional composition that can enhance the effect of red ginseng is urgently needed.
본 발명의 목적은, 홍삼을 경구 섭취할 때, 장 내 존재하는 미생물총을 활성화할 수 있는 물질과 더불어 섭취함으로써, 홍삼의 흡수 효과를 증진시킬 수 있는 기능성 조성물을 제공함에 있다.It is an object of the present invention to provide a functional composition that can enhance the absorption effect of red ginseng by oral ingestion of red ginseng, along with a substance capable of activating the microflora present in the intestine.
본 발명의 목적은, 홍삼을 경구 섭취할 때, 장 내 존재하는 미생물총을 활성화할 수 있는 물질과 더불어 섭취하되, 홍삼 및 장 내 미생물총의 활성화 물질을 모두 분말 형태로 형성함으로써, 섭취 및 휴대가 용이한 기능성 조성물을 제공함에 있다. An object of the present invention, when ingested orally ingested red ginseng, ingested together with a substance capable of activating the microflora present in the intestine, by forming both the active substance of the red ginseng and intestinal microflora in the form of powder, ingestion and carrying It is to provide an easy functional composition.
본 발명은, 홍삼, 혼합 유산균 및 올리고당류를 모두 분말로 형성하여 함유하는 조성물을 제공함으로써, 기술적 과제를 해결하고자 한다.The present invention aims to solve the technical problem by providing a composition containing red ginseng, mixed lactic acid bacteria and oligosaccharides in powder form.
본 발명은, 홍삼2.0중량%, 혼합 유산균 7.5 중량% 및 프락토 올리고당 10 중량%를 모두 분말로 형성하여 함유하되, 식품학적으로 허용 가능한 비타민류, 미네랄류, 산도조절제, 감미제 및 향미제를 추가로 포함하여 100%(w/w)가 되는 조성물을 제공함으로써, 기술적 과제를 해결하고자 한다.The present invention, the red ginseng 2.0% by weight, mixed lactic acid bacteria 7.5% by weight and fructo oligosaccharides containing all 10% by weight of the form, containing vitamins, minerals, acidity regulators, sweetening agents and flavorings By providing a composition comprising 100% (w / w), to solve the technical problem.
본 발명은, 홍삼, 혼합 유산균 및 올리고당류를 모두 분말로 형성하여 스틱(stick) 포장형 제품에 충진하는 건강기능식품을 제공함으로써, 기술적 과제를 해결하고자 한다.The present invention, red ginseng, mixed lactic acid bacteria and oligosaccharides by forming a powder to provide a health functional food to be filled in a stick (pack) packaging type, to solve the technical problem.
본 발명인 홍삼, 혼합 유산균 및 올리고당류를 함유하는 조성물은, 장 내 존재하는 미생물총을 활성화함으로써, 홍삼의 흡수 효과를 증진시킬 수 있는 현저한 효과를 보유하고 있다.The composition containing the red ginseng, mixed lactic acid bacteria and oligosaccharides of the present invention has a remarkable effect of enhancing the absorption effect of red ginseng by activating the microflora present in the intestine.
본 발명인 홍삼, 혼합 유산균 및 올리고당류를 모두 분말로 형성한 조성물을 함유하는 스틱(stick)포장형 건강기능식품은, 섭취 및 휴대가 용이한 현저한 효과를 보유하고 있다. Stick-packed health functional foods containing the composition of the present invention, red ginseng, mixed lactic acid bacteria and oligosaccharides, all in powder form, have a remarkable effect that is easy to ingest and carry.
본 발명인 홍삼, 혼합 유산균 및 올리고당류를 유효성분으로 함유하는 조성물은, 부작용을 가져오지 않으면서 지속적으로 복용함으로써, 홍삼의 건강 증진 기능을 향상시킬 수 있는 현저한 효과를 보유하고 있다.The composition containing the red ginseng, mixed lactic acid bacteria and oligosaccharides of the present invention as an active ingredient has a remarkable effect of improving the health promoting function of red ginseng by continuously taking it without bringing side effects.
도 1 은 본 발명의 실시예에 따른 조성물을 포함하는 식품을 제조하는 방법을 흐름도로서 도시한 도면이다.1 is a flow chart illustrating a method for producing a food comprising a composition according to an embodiment of the present invention.
본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
따라서 본 명세서에 기재된 실시예와 도면에 도시된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.
Therefore, the embodiments described in the present specification and the configurations shown in the drawings are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents It should be understood that water and variations may be present.
이하 첨부된 도면을 참조하여 본 발명의 바람직한 실시예를 상세히 설명하기로 한다.
Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings.
실시예Example
1. One.
홍삼 분말, 혼합 유산균 및 Red ginseng powder, mixed lactic acid bacteria and
올리고당류를Oligosaccharides
함유한 조성물 Containing composition
의of
제조 Produce
본 발명에 사용되는 홍삼 분말은 홍삼 전체를 분쇄 후 가공 처리한 분말 또는 홍삼 농축액 분말 또는 홍삼 추출물 분말을 의미하며, 진세노사이드(ginsenoside) Rb1 및 Rg1의 함량의 합이 3~80mg이 되도록 처리한다.
Red ginseng powder used in the present invention refers to a powder or red ginseng concentrate powder or red ginseng extract powder processed after grinding the whole red ginseng, and treated so that the sum of the contents of ginsenosides Rb1 and Rg1 is 3 to 80 mg. .
본 발명에 사용되는 혼합 유산균은, 락토바실러스(Lactobacillus) 및 비피도박테리움(Bifidobacterium)의 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하되, 코팅 또는 마이크로 캡슐 처리한 분말형태를 의미한다. Mixed lactic acid bacteria used in the present invention, including two or more types of probiotic lactic acid bacteria strains contained in the fungus of Lactobacillus (Lactobacillus) and Bifidobacterium, powder coated or micro-capsulated It means form.
또한 락토바실러스 및 비피도박테리움 균속 이외에도 본 발명의 목적에 적합하다면 다른 균속에 포함된 유산균주를 선택하여 이용할 수 있음은 물론이다.
In addition to the Lactobacillus and Bifidobacterium strains, if suitable for the purposes of the present invention can be used to select the lactic acid strains included in other strains.
본 발명에 사용되는 올리고당류(oligosaccharides)는, 프리바이틱스 (prebiotics)의 개념으로 이용된다.Oligosaccharides used in the present invention are used in the concept of prebiotics.
즉 대장 내에 존재하는 박테리아의 수를 한정하며 선택적으로 박테리아의 성장을 자극하여 인체에 유리한 영향을 주는 물질로서 이용된다.That is, it limits the number of bacteria present in the large intestine and selectively stimulates the growth of bacteria, which is used as a substance having a beneficial effect on the human body.
프락토 올리고당, 이눌린, 유과올리고당, 락툴로스 등의 올리고당 류에서 선택적으로 포함시키되, 본 발명의 조성물에 사용되는 유산균의 종류에 따라 선택되도록 한다.It is optionally included in oligosaccharides such as fructo oligosaccharide, inulin, fructose oligosaccharide, lactulose, etc., so as to be selected according to the type of lactic acid bacteria used in the composition of the present invention.
또한 상기 열거한 올리고당류 이외에도 본 발명의 목적에 적합하다면 다른 올리고당류를 선택하여 이용할 수 있음은 물론이다.
In addition to the above-mentioned oligosaccharides, other oligosaccharides may be selected and used if suitable for the purposes of the present invention.
본 발명의 실시예에 따른 홍삼 분말, 혼합 유산균 및 올리고당류를 포함하는 조성물에, 약제학적으로 허용되는 담체, 부형제 또는 희석제 등을 추가하여 약제학적 단위 투여형을 제공하도록 할 수 있다.To a composition comprising red ginseng powder, mixed lactic acid bacteria and oligosaccharides according to an embodiment of the present invention, a pharmaceutically acceptable carrier, excipient or diluent may be added to provide a pharmaceutical unit dosage form.
여기에서, 담체, 부형제, 희석제로는 토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Examples of the carrier, excipient and diluent include tosse, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Vaginal cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
또한 상기 약제학적 투여 형태는 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다.
The pharmaceutical dosage forms may also be used in the form of pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable set.
또한 상기 홍삼 분말, 혼합 유산균 및 올리고당류를 포함하는 조성물을 제제화 할 경우에는 통상적으로 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면 활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.
In addition, when formulating a composition comprising the red ginseng powder, mixed lactic acid bacteria and oligosaccharides, it may be prepared using a diluent or excipient such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used.
또한 상기 약제학적 투여 형태는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 좌제, 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다.In addition, the pharmaceutical dosage forms may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. .
상기 경구 투여를 위한 고형 제제에는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분은 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다.The solid preparation for oral administration may be prepared by mixing at least one excipient, for example starch, with calcium carbonate, sucrose or lactose, gelatin, and the like in the extract. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
상기 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. The preparation for parenteral administration may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, and a suppository.
상기 비 수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸 올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.
Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 실시예에 따른 유효성분의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 연령, 성별, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.
The preferred dosage of the active ingredient according to an embodiment of the present invention depends on the condition and weight of the patient, the extent of the disease, age, sex, drug form, route of administration and duration, but may be appropriately selected by those skilled in the art.
본 발명의 추출물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하주사에 의해 투여될 수 있다.
The extract of the present invention can be administered to mammals such as rats, mice, livestock, humans and the like in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, muscular, subcutaneous injection.
본 발명의 실시예에 따른 홍삼 분말, 혼합 유산균 및 올리고당류를 포함하는 조성물에 따른 유효성분에, 식품 보조 첨가제를 추가하여 건강 기능성 식품을 제공할 수 있다.To the active ingredient according to the composition comprising a red ginseng powder, mixed lactic acid bacteria and oligosaccharides according to an embodiment of the present invention, food supplements can be added to provide a health functional food.
상기 성분을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다.Examples of the food to which the above components can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods.
또한 항산화 기능을 목적으로 한 식품 또는 음료에 첨가될 수 있다.It may also be added to foods or beverages for the purpose of antioxidant function.
이때, 식품 또는 음료 중의 상기 성분의 양은 전체 식품 중량의 0.01 내지 20 중량% 이 될 수 있으며, 건강 음료 조성물은 100 ml를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다.
At this time, the amount of the ingredient in the food or beverage may be 0.01 to 20% by weight of the total food weight, the health beverage composition may be added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml have.
본 발명의 건강 기능성 음료 조성물은 상기 성분을 함유하는 외의 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health functional beverage composition of the present invention is not particularly limited to the other components containing the above components, and may contain various flavors or natural carbohydrates, etc. as additional components, as in general beverages.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당; 디사카라이드, 예를 들어 말토스, 슈크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외에 향미제로써 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the aforementioned natural carbohydrates include monosaccharides such as glucose, fructose; Disaccharides such as maltose, sucrose and the like and polysaccharides such as dextrins, cyclodextrins and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. In addition to the above, natural flavoring agents (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavorings.
상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.
The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 성분은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 추가로 함유할 수 있다.In addition to the above, the ingredients of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, organic acids, and protection. It may further contain a sex colloid thickener, a pH adjuster, a stabilizer, a preservative, a glycerin, an alcohol, a carbonation agent used in a carbonated beverage, and the like.
그 밖에 본 발명의 성분은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the components of the present invention may contain natural fruit juices and pulp for the production of fruit juice beverages and vegetable beverages.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 추출물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
These components may be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the extract of the present invention.
제조예1. 홍삼 분말, 혼합 유산균 및 올리고당류를 함유한 식품의 제조 Preparation Example 1. Preparation of Foods Containing Red Ginseng Powder, Mixed Lactic Acid Bacteria and Oligosaccharides
본 발명에 사용되는 홍삼 분말은 홍삼 전체를 분쇄 후 가공 처리한 분말 또는 홍삼 농축액 분말 또는 홍삼 추출물 분말을 의미하며, 진세노사이드(ginsenoside) Rb1 및 Rg1의 함량의 합이 3~80mg이 되도록 처리한다. Red ginseng powder used in the present invention refers to a powder or red ginseng concentrate powder or red ginseng extract powder processed after grinding the whole red ginseng, and treated so that the sum of the contents of ginsenosides Rb1 and Rg1 is 3 to 80 mg. .
홍삼 분말은 총 중량 기준 0.1~5 중량 %로 선택되며, 바람직하게 2.0 중량 %로 선택될 수 있다.
The red ginseng powder is selected from 0.1 to 5% by weight based on the total weight, preferably 2.0% by weight.
본 발명에 사용되는 혼합 유산균은, 락토바실러스(Lactobacillus) 및 비피도박테리움(Bifidobacterium)의 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하되, 코팅 또는 마이크로 캡슐 처리한 분말형태를 의미한다. Mixed lactic acid bacteria used in the present invention, including two or more types of probiotic lactic acid bacteria strains contained in the fungus of Lactobacillus (Lactobacillus) and Bifidobacterium, powder coated or micro-capsulated It means form.
또한 락토바실러스 및 비피도박테리움 균속 이외에도 본 발명의 목적에 적합하다면 다른 균속에 포함된 유산균주를 선택하여 이용할 수 있음은 물론이다.In addition to the Lactobacillus and Bifidobacterium strains, if suitable for the purposes of the present invention can be used to select the lactic acid strains included in other strains.
바람직하게, 혼합 유산균은 7.5 중량 %로 선택되어 이용된다.
Preferably, the mixed lactic acid bacteria is selected and used at 7.5% by weight.
본 발명에 사용되는 올리고당류(oligosaccharides)는 프락토 올리고당, 이눌린, 유과올리고당, 락툴로스 등의 올리고당 류에서 선택적으로 포함시키되, 본 발명의 조성물에 사용되는 유산균의 종류에 따라 선택되도록 하며, 상기 열거한 올리고당류 이외에도 본 발명의 목적에 적합하다면 다른 올리고당류를 선택하여 이용할 수 있음은 물론이다.Oligosaccharides used in the present invention may be optionally included in oligosaccharides such as fructo oligosaccharide, inulin, fructose oligosaccharide, lactulose, and the like, and are selected according to the type of lactic acid bacteria used in the composition of the present invention. In addition to one oligosaccharide, other oligosaccharides may be selected and used if suitable for the purposes of the present invention.
바람직하게, 프락토 올리고당(Fructo-oligosaccharides)을 사용하되 10 중량 %로 선택되어 이용된다.
Preferably, fructo-oligosaccharides are used but selected by weight of 10% by weight.
본 발명은 주요 성분으로서의 홍삼 분말, 혼합 유산균 및 프락토 올리고당 이외에 비타민류, 미네랄류, 산도조절제, 향미제, 감미제 및 당류 등을 추가로 포함하여 혼합되며, 추가로 포함되는 성분은 다음과 같다.The present invention is mixed with red ginseng powder, mixed lactic acid bacteria and fructo oligosaccharides as main components, including vitamins, minerals, acidity regulators, flavoring agents, sweeteners and sugars, and the like.
비타민C 0.8중량%, 비타민 E 0.1 중량%, 비타민 B1 0.007중량%, 비타민 B6 0.01중량%, 비타민 B2 0.009중량%, 산화아연 0.02중량%, 밀크칼슘 2 중량%, 구연산 1.8 중량%, 오렌지과즙분말 1.0중량%, 식물성크림분말 10 중량%, 니코틴산아미드 0.095 중량%, 콜라겐 2.5 중량%, 판토텐산칼슘 0.035 중량%, 자일리톨 5 중량%, 스테아린산마그네슘 0.5 중량% 이며, 이후 100%(w/w)가 되도록 정제 포도당으로 조정한다.
Vitamin C 0.8%, Vitamin E 0.1%, Vitamin B1 0.007%, Vitamin B6 0.01%, Vitamin B2 0.009%, Zinc Oxide 0.02%, Milk Calcium 2%, Citric Acid 1.8%, Orange Juice Powder 1.0 wt%, vegetable cream powder 10 wt%, nicotinic acid amide 0.095 wt%, collagen 2.5 wt%, calcium pantothenate 0.035 wt%, xylitol 5 wt%, magnesium stearate 0.5 wt%, then 100% (w / w) Adjust to purified glucose.
참고Reference
예Yes
1. One.
스틱stick
(stick) (stick)
포장형Package
식품으로 제조하는 방법 How to make food
본 발명의 실시예 및 제조예에 따른 조성물은 분말형태로서 혼합되어서, 섭취 및 휴대가 용이하도록 스틱(stick) 포장형 제품(2~10g 단위포장의 분말조성)으로 제조될 수 있다.
Compositions according to embodiments and preparations of the present invention may be mixed as a powder form, and may be prepared as a stick packaged product (powder composition of 2 to 10 g unit packaging) for easy ingestion and portability.
도 1 은 본 발명의 실시예에 따른 조성물을 포함하는 식품을 제조하는 방법을 흐름도로서 도시한 도면이다.
1 is a flow chart illustrating a method for producing a food comprising a composition according to an embodiment of the present invention.
먼저, 공정서 규격에 따른 원료검사를 수행하고, 칭량 과정에서는 기본 규격에 적합한 원료를 사용했는지 및 사용기구, 기계의 청결 여부를 확인하며 또한 교차 오염을 점검하게 된다.First, the raw material inspection according to the process standard is performed, and in the weighing process, it is checked whether the raw material suitable for the basic standard is used and the cleanliness of the use equipment and the machine, and the cross contamination is also checked.
혼합 과정에서는 혼합기 회전수 30rpm으로 20~30분간 혼합을 하며, 충진 과정에서는 스틱 포장기를 이용하여 충진하되 중량 편차가 2000mg/포±3%가 되도록 한다.In the mixing process, the mixture is mixed for 30 to 30 minutes at 30 rpm of the mixer. In the filling process, the filling is performed using a stick packing machine, but the weight deviation is 2000 mg / po ± 3%.
반제품 검사 과정에서는, 반제품 규격 및 기준에 따른 적합성 시험, 미생물 시험 등을 수행하며, 완제품 검사에는 성상, 수분, 대장군균 및 프로바이오틱수를 검사한 후, 출고하게 된다.In the semi-finished product inspection process, conformity tests and microbial tests according to semi-finished product specifications and standards are performed, and finished product inspection is carried out after inspection of properties, moisture, E. coli and probiotic water.
Claims (9)
(a) 상기 홍삼 분말은 0.1 ~ 5중량% 포함하되, 진세노사이드(ginsenoside) Rb1 및 Rg1의 함량의 합이 3 ~ 80mg이 되도록 하고,
(b) 상기 혼합 유산균은 7.5 중량% 포함하되, 락토바실러스(Lactobacillus) 및 비피도박테리움(Bifidobacterium) 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하여 상기 홍삼 분말의 흡수를 증진하는 효능을 갖도록 하고,
(c) 상기 올리고당류는 프락토 올리고당(Fructo-oligosaccharides) 10 중량% 포함하여 장내 미생물총의 활성을 자극하는 효능을 갖도록 하는 것을 특징으로 하는 조성물.
Red ginseng ( Panax ginseng CA Meyer), mixed lactic acid bacteria and oligosaccharides are all formed as powders, and 100% (including food-acceptable vitamins, minerals, acidity regulators, sweeteners and flavoring agents). w / w)
(a) the red ginseng powder contains 0.1 to 5% by weight, and the sum of the contents of ginsenosides Rb1 and Rg1 is 3 to 80 mg,
(b) the mixed lactic acid bacteria contained 7.5% by weight, including two or more types of probiotic lactic acid bacteria strains included in Lactobacillus and Bifidobacterium strains to absorb the red ginseng powder Have the effect of promoting
(c) The oligosaccharide composition comprising 10% by weight of fructo oligosaccharides (Fructo-oligosaccharides) to have the effect of stimulating the activity of the intestinal microflora.
(a) 상기 홍삼 분말은 0.1 ~ 5중량% 포함하되, 진세노사이드(ginsenoside) Rb1 및 Rg1의 함량의 합이 3 ~ 80mg이 되도록 하고,
(b) 상기 혼합 유산균은 7.5 중량% 포함하되, 락토바실러스(Lactobacillus) 및 비피도박테리움(Bifidobacterium) 균속에 포함되는 프로바이오틱(probiotic) 유산균주를 2개 종류 이상 포함하여 상기 홍삼 분말의 흡수를 증진하는 효능을 갖도록 하고,
(c) 상기 올리고당류는 프락토 올리고당(Fructo-oligosaccharides) 10 중량% 포함하여 장내 미생물총의 활성을 자극하는 효능을 갖도록 하는 것을 특징으로 하는 건강기능식품.
Red ginseng ( Panax ginseng CA Meyer), mixed lactic acid bacteria and oligosaccharides are all formed as powders, and 100% (including food-acceptable vitamins, minerals, acidity regulators, sweeteners and flavoring agents). w / w)
(a) the red ginseng powder contains 0.1 to 5% by weight, and the sum of the contents of ginsenosides Rb1 and Rg1 is 3 to 80 mg,
(b) the mixed lactic acid bacteria contained 7.5% by weight, including two or more types of probiotic lactic acid bacteria strains included in Lactobacillus and Bifidobacterium strains to absorb the red ginseng powder Have the effect of promoting
(c) The oligosaccharides containing 10% by weight of fructo oligosaccharides (Fructo-oligosaccharides) health functional foods, characterized in that to have the effect of stimulating the activity of the intestinal microflora.
상기 홍삼, 혼합 유산균, 올리고당류 및 식품학적으로 허용 가능한 비타민류, 미네랄류, 산도조절제, 감미제, 향미제는 스틱(stick) 포장형 제품에 분말로 충진되는 것을 특징으로 하는 건강기능식품.The method according to claim 6,
The red ginseng, mixed lactic acid bacteria, oligosaccharides and food acceptable vitamins, minerals, acidity regulators, sweetening agents, flavoring agents, characterized in that the filling (stick) packaged products in the health functional food.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110027290A KR101266148B1 (en) | 2011-03-28 | 2011-03-28 | A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110027290A KR101266148B1 (en) | 2011-03-28 | 2011-03-28 | A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120109119A KR20120109119A (en) | 2012-10-08 |
KR101266148B1 true KR101266148B1 (en) | 2013-05-21 |
Family
ID=47280545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110027290A KR101266148B1 (en) | 2011-03-28 | 2011-03-28 | A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101266148B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220108452A (en) | 2021-01-27 | 2022-08-03 | 충청대학교 산학협력단 | Method for manufacturing lactic acid bacteria preparation containing fruits |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101440685B1 (en) * | 2012-10-17 | 2014-09-19 | 주식회사 풀무원 | Composition for promoting absorption of ginseng saponin by synbiotics |
CN104068406A (en) * | 2014-01-15 | 2014-10-01 | 洪文平 | Mental and physical exhaustion alleviating dietary |
CN104055106A (en) * | 2014-01-15 | 2014-09-24 | 洪文平 | Diet for recuperating congestion disease |
KR101765559B1 (en) * | 2016-09-27 | 2017-08-07 | 이대희 | Probiotics composition containing hericium erinaceus |
CN107927780A (en) * | 2017-11-28 | 2018-04-20 | 戴凤 | Probiotics soft capsule containing natural extract |
KR101982223B1 (en) | 2017-11-30 | 2019-05-24 | 주식회사 비케이바이오 | METHOD FOR PREPARING OLIGOSACCHARIDES USING Leuconostoc lactis CCK940 |
KR102121330B1 (en) * | 2019-08-09 | 2020-06-11 | (주)제이비 바이오 | Highly functional ginseng concentrate granule and its preparation method |
KR102255977B1 (en) * | 2019-10-23 | 2021-05-25 | 주식회사 한국인삼공사 | Method for Preparing Pills Comprising Ginseng |
CN116998724A (en) * | 2023-06-28 | 2023-11-07 | 安琪生物科技有限公司 | Preparation and application of lactobacillus living bacteria and gastrodia elata polysaccharide composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100444396B1 (en) * | 2001-11-20 | 2004-08-16 | 주식회사 한국인삼공사 | A healthful food for eating raw |
-
2011
- 2011-03-28 KR KR1020110027290A patent/KR101266148B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100444396B1 (en) * | 2001-11-20 | 2004-08-16 | 주식회사 한국인삼공사 | A healthful food for eating raw |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220108452A (en) | 2021-01-27 | 2022-08-03 | 충청대학교 산학협력단 | Method for manufacturing lactic acid bacteria preparation containing fruits |
Also Published As
Publication number | Publication date |
---|---|
KR20120109119A (en) | 2012-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101266148B1 (en) | A pharmaceutical comprising Panax Ginseng, mixed lactic acid bacteria and oligosaccharides, and a healthful food with the pharmaceutical | |
KR101326005B1 (en) | Functional beverage composition comprising Panax Ginseng concentrate and fruit concentrate | |
WO2007133054A1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
KR101614574B1 (en) | Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange | |
KR100749229B1 (en) | Composition for improving constipation comprising sugar and sugar alcohols | |
US20080020067A1 (en) | Skin Moisturizer | |
KR100549089B1 (en) | A Health Care Composition for treating or preventing intestinal disease and constipation | |
WO2008075866A1 (en) | A composition comprising the processed extract of panax quinquefolium l. for the prevention and treatment of cancer | |
JP6861169B2 (en) | Compositions for Weight Loss Containing Beverages and Beads | |
JP2010275288A (en) | Functional composition for preventing and improving hangover, food and food additive containing the same | |
KR100696589B1 (en) | Composition comprising the extract of Theragra chalcogramma, Hovenia dulcis and Viscum album var. coloratum and catechins of Pueraria thunbergiana for treating or alleviating hangover syndrom and protecting liver | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR100506824B1 (en) | Crude Drug Compositions for treating or preventing intestinal disease and constipation | |
KR102410771B1 (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
KR102014922B1 (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
CN104146241A (en) | Health composition capable of benefiting bodies and relaxing bowels and preparation method of health composition | |
KR101016837B1 (en) | Composition comprising the extract of Lonicera japonica THUNB. preventing and treating arthritis | |
KR101470347B1 (en) | A Composition Comprising the Fermentate of Scutellariae Radix extract for protecting liver damage | |
CN105685968A (en) | Composition for supplementing calcium and vitamins to children as well as preparation method and application of composition | |
CN111887332A (en) | Konjak chocolate capable of dispelling effects of alcohol, protecting liver and benefiting intestines and preparation method thereof | |
CN110710672A (en) | Natural plant active calcium preparation and preparation method thereof | |
JP5176176B2 (en) | Improved lipid metabolism, food and drink, and pharmaceuticals | |
KR20050041272A (en) | Composition comprising the extract of complex hurb medicines for growth stimulation, or treatment and prevention of growth retardation | |
KR20140043176A (en) | Pharmacological composition for prevention and treatment of liver injury, and functional food including thereof | |
KR20210086030A (en) | Simplicity food composition for containing red jinseng and lactobacillus, and the simplicity food contained the composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160512 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20170511 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20180605 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20190513 Year of fee payment: 7 |